Business Context and Reporting Period
Company: Pacific Biosciences of California, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 8, 2013
Event: Entry into a Material Definitive Agreement (Amendment No. 1 to Controlled Equity Offering Sales Agreement).
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, or debt levels. The filing focuses exclusively on a capital raising mechanism.
- Aggregate Offering Price: Up to $30.0 million in common stock.
- Commission Rate: 3.0% of the gross sales price per share sold to the sales agent (Cantor Fitzgerald & Co.).
- Use of Proceeds: General corporate purposes, including capital expenditures and working capital.
Material Changes
The Company amended its existing Controlled Equity Offering Sales Agreement dated October 5, 2012. The material change is the authorization to offer and sell an additional $30.0 million worth of shares. This amount is in addition to any shares remaining unsold under the original agreement.
Outlook, Risks, and Unusual Items
Management Commentary: The Company intends to use the proceeds for general corporate purposes, capital expenditures, and working capital. Sales will be conducted "at-the-market" or through privately negotiated transactions based on Company instructions.
Terms and Conditions:
- The Company is not obligated to make any sales of the shares under the agreement.
- The offering terminates upon the sale of all shares or termination by either party.
- Sales are subject to applicable state and federal laws and NASDAQ rules.
Risks: The filing notes that the report does not constitute an offer to sell in any state where such offer would be unlawful prior to registration.
Investor Verification Checklist
- Verify the total number of shares previously sold under the original October 5, 2012 agreement to assess total potential dilution.
- Review the filed Prospectus Supplement (dated November 12, 2013) and Registration Statement (File No. 333-180533) for detailed terms.
- Monitor future 8-K filings or quarterly reports to track the actual volume of shares sold under this new $30.0 million authorization.
- Confirm the Company's current cash position and burn rate to evaluate the necessity of this capital raise for working capital.